{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:50:46Z","timestamp":1781509846176,"version":"3.54.1"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Norwegian ExtraFoundation for Health and Rehabilitation"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0166451","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T14:10:38Z","timestamp":1479219038000},"page":"e0166451","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5043-5107","authenticated-orcid":true,"given":"H\u00e5vard","family":"Midgard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen G.","family":"Bramness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Skurtveit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Haukeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Dalgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,11,15]]},"reference":[{"issue":"9791","key":"ref1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"PK Nelson","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"E Gower","year":"2014","journal-title":"Journal of hepatology"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2893.2010.01279.x","article-title":"Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents","volume":"18","author":"J Grebely","year":"2011","journal-title":"Journal of viral hepatitis"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2012.08.024","article-title":"All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study","volume":"58","author":"KB Kielland","year":"2013","journal-title":"Journal of hepatology"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"B Hajarizadeh","year":"2013","journal-title":"Nature reviews Gastroenterology & hepatology"},{"issue":"Suppl 2","key":"ref6","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/cit306","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis","volume":"57","author":"EJ Aspinall","year":"2013","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/cid\/cis1007","article-title":"Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis","volume":"56","author":"RB Dimova","year":"2013","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"ref8","unstructured":"AASLD-IDSA. AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus. Available: http:\/\/www.hcvguidelines.org<\/ext-link>. Accessed 20 June 2016. (Archived by WebCite\u00ae at http:\/\/www.webcitation.org\/6iPAiC0wA<\/ext-link>). 2015."},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.drugpo.2015.07.005","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"26","author":"J Grebely","year":"2015","journal-title":"The International journal on drug policy"},{"key":"ref10","unstructured":"WHO. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Available: http:\/\/www.who.int\/hepatitis\/publications\/hepatitis-c-guidelines-2016\/en\/<\/ext-link>. 2016."},{"key":"ref11","article-title":"EASL Recommendations on Treatment of Hepatitis C 2016","year":"2016","journal-title":"Journal of hepatology"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"SH Mehta","year":"2008","journal-title":"Journal of community health"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2893.2009.01080.x","article-title":"Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents","volume":"16","author":"J Grebely","year":"2009","journal-title":"Journal of viral hepatitis"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/liv.12370","article-title":"Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents","volume":"34","author":"M Alavi","year":"2014","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jvh.12129","article-title":"Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999\u20132011","volume":"21","author":"J Iversen","year":"2014","journal-title":"Journal of viral hepatitis"},{"issue":"Suppl 1","key":"ref16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jvh.12248","article-title":"The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm","volume":"21","author":"H Razavi","year":"2014","journal-title":"Journal of viral hepatitis"},{"issue":"Suppl 1","key":"ref17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jvh.12351","article-title":"The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm\u2014volume 2","volume":"22","author":"A Hatzakis","year":"2015","journal-title":"Journal of viral hepatitis"},{"issue":"Suppl 1","key":"ref18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1478-3231.2011.02706.x","article-title":"Barriers to hepatitis C treatment","volume":"32","author":"CE McGowan","year":"2012","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/jvh.12008","article-title":"Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers","volume":"19","author":"P Bruggmann","year":"2012","journal-title":"Journal of viral hepatitis"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/hep.26246","article-title":"A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care","volume":"57","author":"CE McGowan","year":"2013","journal-title":"Hepatology"},{"key":"ref21","article-title":"An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential","author":"DC Perlman","year":"2015","journal-title":"The International journal on drug policy"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1360-0443.2012.03932.x","article-title":"Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings","volume":"107","author":"P Vickerman","year":"2012","journal-title":"Addiction"},{"issue":"Suppl 2","key":"ref23","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"NK Martin","year":"2013","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.20279","article-title":"A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance","volume":"40","author":"S Mauss","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.drugalcdep.2006.09.018","article-title":"Referral for chronic hepatitis C treatment from a drug dependency treatment setting","volume":"88","author":"R Hallinan","year":"2007","journal-title":"Drug and alcohol dependence"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000104884","article-title":"Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study","volume":"13","author":"AL Krook","year":"2007","journal-title":"European addiction research"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsat.2008.09.009","article-title":"Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program","volume":"37","author":"AH Litwin","year":"2009","journal-title":"Journal of substance abuse treatment"},{"key":"ref28","first-page":"w13193","article-title":"Management of hepatitis C virus (HCV) infection in drug substitution programs","volume":"141","author":"A Witteck","year":"2011","journal-title":"Swiss medical weekly"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1360-0443.2010.03347.x","article-title":"Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy","volume":"106","author":"JJ Sasadeusz","year":"2011","journal-title":"Addiction"},{"issue":"Suppl 2","key":"ref30","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/cid\/cit305","article-title":"Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study","volume":"57","author":"M Alavi","year":"2013","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.2105\/AJPH.2013.301458","article-title":"A randomized trial of a hepatitis care coordination model in methadone maintenance treatment","volume":"103","author":"CL Masson","year":"2013","journal-title":"American journal of public health"},{"issue":"Suppl 2","key":"ref32","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/cid\/cit271","article-title":"Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all","volume":"57","author":"P Bruggmann","year":"2013","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/add.13197","article-title":"Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study","volume":"111","author":"J Grebely","year":"2016","journal-title":"Addiction"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1177\/145507251002700106","article-title":"Hard drug use in Norway","volume":"27","author":"EJ Amundsen","year":"2010","journal-title":"Nordic Studies on Alcohol and Drugs"},{"key":"ref35","unstructured":"Skretting A. BEK, Ved\u00f8y, T. F., Lund, K. E. Drug use in Norway. SIRUS report 2015. The Norwegian Institute for Alcohol and Drug Research. Available: http:\/\/wpstatic.idium.no\/www.sirus.no\/2015\/12\/rusmidler_i_norge2015.pdf<\/ext-link>. Accessed 20 June 2016. (Archived by WebCite\u00ae at http:\/\/www.webcitation.org\/6iPCCbZEJ<\/ext-link>)."},{"key":"ref36","unstructured":"Waal H, Busserud K, Clausen T, Skeie I, H\u00e5seth A, Lillevold H. Annual assessment of the Norwegian OMT program 2016. SERAF, University of Oslo. Avaiable: http:\/\/www.oslo-universitetssykehus.no\/SiteCollectionDocuments\/Omoss\/Avdelinger\/Psykiskhelseogavhengighet\/Rus-ogavhengighetsbehandling\/NasjonalkompetansetjenesteTSB\/seraf-rapport-nr-1-2016-statusrapport-2015.pdf<\/ext-link>. Accessed 20 June 2016. (Archived by WebCite\u00ae at http:\/\/www.webcitation.org\/6iPCcZGfV<\/ext-link>)."},{"issue":"2","key":"ref37","first-page":"101","article-title":"Risk factors for hepatitis C among injecting drug users in Oslo","volume":"129","author":"O Dalgard","year":"2009","journal-title":"Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke"},{"key":"ref38","article-title":"WHO Collaborating Centre for Drug Statistics Methodology"},{"issue":"2","key":"ref39","first-page":"66","article-title":"Merits and problems in high-threshold methadone maintenance treatment. Evaluation of medication-assisted rehabilitation in Norway 1998\u20132004","volume":"13","author":"H Waal","year":"2007","journal-title":"European addiction research"},{"key":"ref40","unstructured":"National guidelines for opioid substitution treatment 2010. The Norwegian Directorate of Health. Available: https:\/\/helsedirektoratet.no\/Lists\/Publikasjoner\/Attachments\/100\/IS-1701-Legemiddelassistert-rehabilitering-ved-opioidavhengighet.pdf<\/ext-link>. Accessed 20 June 2016. (Archived by WebCite\u00ae at http:\/\/www.webcitation.org\/6iPB3f7a0<\/ext-link>)."},{"issue":"9","key":"ref41","first-page":"926","article-title":"Treatment of chronic hepatitis C","volume":"122","author":"H Bell","year":"2002","journal-title":"Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke"},{"key":"ref42","unstructured":"Norwegian Institute of Public Health. Available: https:\/\/wwwfhino\/nettpub\/smittevernveilederen\/sykdommer-a-a\/hepatitt-c\u2014veileder-for-helsepers\/-forekomst-i-norge<\/ext-link>. 2016."},{"key":"ref43","unstructured":"Dalgard O, Bj\u00f8ro K, M\u00e6land A, Konopski Z, Karlsen L, Sandvei P, et al. Norwegian guidelines for assessment and treatment of hepatitis C infection 2015. Available: http:\/\/www.hepatittfag.no<\/ext-link>. Accessed 20 June 2016. (Archived by WebCite\u00ae at http:\/\/www.webcitation.org\/6iPBWGkvc<\/ext-link>)."},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.addbeh.2014.05.007","article-title":"Factors associated with dropout among patients in opioid maintenance treatment (OMT) and predictors of re-entry. A national registry-based study","volume":"39","author":"A Bukten","year":"2014","journal-title":"Addictive behaviors"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.3109\/00365521.2014.968860","article-title":"HCV treatment uptake in people who have injected drugs\u2014observations in a large cohort that received addiction treatment 1970\u20131984","volume":"49","author":"KB Kielland","year":"2014","journal-title":"Scandinavian journal of gastroenterology"},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jhep.2013.09.022","article-title":"Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort study","volume":"60","author":"KB Kielland","year":"2014","journal-title":"Journal of hepatology"},{"issue":"4","key":"ref47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0031-1297922","article-title":"What is killing people with hepatitis C virus infection?","volume":"31","author":"J Grebely","year":"2011","journal-title":"Seminars in liver disease"},{"issue":"2\u20133","key":"ref48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.drugalcdep.2007.03.008","article-title":"Benzodiazepine prescription for patients in opioid maintenance treatment in Norway","volume":"90","author":"JG Bramness","year":"2007","journal-title":"Drug and alcohol dependence"},{"issue":"4","key":"ref49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","article-title":"Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C","volume":"8","author":"MS Sulkowski","year":"2011","journal-title":"Nature reviews Gastroenterology & hepatology"},{"issue":"7","key":"ref50","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/cid\/cit377","article-title":"Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements","volume":"57","author":"J Grebely","year":"2013","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2014.01.002","article-title":"Can hepatitis C virus infection be eradicated in people who inject drugs?","volume":"104","author":"J Grebely","year":"2014","journal-title":"Antiviral research"},{"issue":"6","key":"ref52","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/QCO.0000000000000216","article-title":"Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence","volume":"28","author":"M Hickman","year":"2015","journal-title":"Current opinion in infectious diseases"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0166451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T12:22:38Z","timestamp":1568550158000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0166451"}},"subtitle":[],"editor":[{"given":"Yury E","family":"Khudyakov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,15]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0166451","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,15]]}}}